National Institutes of Health (NIH)
National Cancer Institute (NCI)
R50 Research Specialist Award
This notice of funding opportunity (NOFO) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This NOFO is specifically targeted toward laboratory-based scientists.
The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.
30 days prior to the application due date .
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
November 02, 2023 | November 02, 2023 | Not Applicable | March 2024 | May 2024 | July 2024 |
November 01, 2024 | November 01, 2024 | Not Applicable | March 2025 | May 2025 | July 2025 |
November 03, 2025 | November 03, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Not Applicable
It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts).
Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.
Applications that do not comply with these instructions may be delayed or not accepted for review.
There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.
This notice of funding opportunity (NOFO) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This NOFO is specifically targeted toward laboratory-based scientists.
The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise.It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.
The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI-funded grants held by others for cancer research career continuity. Over the past decade, there has been a major expansion in the scope of approaches, technologies, and expertise required to effectively address any research question. A typical research activity includes molecular, genomic, phenotypic, and functional characterizations, each of which entails sophisticated technologies and understanding (e.g., deep sequencing, bioinformatics, imaging, flow cytometry, animal modeling, etc.). Accompanying the increases in the number of required approaches is the growing need for exceptional scientists with extensive research experience in each of those areas who provide continuity, stability, and detailed scientific knowledge beyond that of a technician or a trainee. There is already a clustering of individual small research groups around central cores that specialize in different expertise (e.g., nuclear magnetic resonance [NMR], mass spectrometry [MS], sequencing, fluorescence-activated cell sorting [FACS], biochemistry, animal models, etc.), such that many experiments are performed, at least in part, through such cores. In addition, with the generation of large datasets ("big data") that are publicly available, there is a growing need for computational experts within many research programs or departments that previously did not rely on these skill sets. Data scientists (e.g., informaticians, statisticians, epidemiologists, behavioral scientists, and population scientists) are found primarily in computational biology groups or in data-rich big science groups. The need for such individuals is rapidly expanding to many other types of research groups.
There has been a continuing shift in the way research is organized, with increased reliance on a cadre of Research Specialists in laboratories, cores, and other scientific support facilities. Extramural institutions have begun to address the need for such scientists by providing staff support for cores that serve multiple research programs. Moreover, individual research programs have created Research Specialist positions using their grant support. However, neither of these positions currently provides the individual with either the recognition or independent funding that will attract and maintain the best scientists. These examples and many others highlight the need to create a career path for highly trained researchers who will play an increasingly important role in advancing biomedical research.
The Research Specialist Award (Lab Scientist) is intended to provide salary support for a sustained period of time and encourage the development of a stable career for exceptional researchers who want to pursue particular research activities within the context of a research program, but not be independent investigators. These scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. The award is intended for laboratory research-oriented investigators with significant, relevant experience, who have shown clear evidence of productivity and research excellence in the field of their training and would like to support a particular research activity (e.g., a research program), with the goal of making significant contributions to behavioral, biomedical (basic or clinical), computational, bioimaging or bioengineering research that is relevant to the NCI mission. The proposed new research support is intended to provide salaries and sufficient autonomy so that individuals are not solely dependent on NCI-funded grants held by others for career continuity. As the PD/PI, Research Specialists would have the option, with prior NCI approval, to move to other research programs or institutions while maintaining funding from this award (e.g., if the Unit Director's laboratory is closed, etc.).
The Unit Director must be an NCI-funded Program Director/Principal Investigator (PD/PI) with an established working relationship with the Research Specialist. The Research Specialist must be supported by the Unit Director's NCI-funded grant(s) as described below. Furthermore, the Unit Director must be the PD/PI of NCI funded research grant(s) that have at least 1 full funding year remaining (exclusive of no cost extensions and supplements) at the time of award of the R50. The Unit Director, together with the Research Specialist, is responsible for planning, directing, monitoring, and executing the NCI-funded research currently being conducted within the laboratory. Only one Unit Director may be designated on an application.
Special Note: Applicants must note the requirements for eligibility of this program, the required biosketches and letters of support - applications that are incomplete or non-compliant will not be reviewed.
See Section VIII. Other Information for award authorities and regulations.
Grant: A support mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Not Allowed: Only accepting applications that do not propose clinical trials.
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Application budgets may request the following two expenses in direct costs per year:
1) salary support for the Research Specialist commensurate with their level of funded effort (not less than 6 person-months) on NCI-funded research grants during:
2) travel costs to attend research meetings/conferences not to exceed $2,500 per year.
The total award project period may not exceed 5 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
1. Eligible Applicants
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Local Governments
Other
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019.
The Research Specialist must be the PD/PI of the application.The Unit Director must not be the PD/PI. However, the Unit Director must be included as Senior/Key Personnel participating as an Other Significant Contributor.
Both the Research Specialist and the Unit Director must include a NIH Biosketch.
See Additional Information on Eligibility for requirements for the Unit Director.
Additional Eligibility Requirements:
2. Cost Sharing
This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement.
3. Additional Information on Eligibility
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
1. Requesting an Application Package
The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
2. Content and Form of Application Submission
It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6266
Email: siemonc@mail.nih.gov
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this NOFO.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Both the R50 PI and Unit Director must include a Biosketch.
R&R Budget
All instructions in the SF424 (R&R) Application Guide must be followed.
Application budgets may request the following two expenses in direct costs per year:
1) salary support for the Research Specialist commensurate with their level of funded effort on the Unit Director's NCI-funded research grants (where the Unit Director is the PD/PI) during:
2) travel costs to attend research meetings/conferences not to exceed $2,500 per year.
R&R Subaward Budget
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Specific Aims: Do not use. Specific Aims are not allowed.
Research Strategy: Upload the Research Strategy as a single attachment and organize the Research Strategy using the instructions provided below. Start each section of the document with the appropriate section heading:
1) Research Program(s) engaging the Research Specialist's activity/effort: Describe the NCI-funded research program(s) of the Unit Director's laboratory which the Research Specialist currently supports. Explain the spectrum and type of research program/lab to which the Research Specialist currently contributes and is likely to contribute in the future.
2) Role of the Research Specialist in Research Program(s): Describe the particular activity of the Research Specialist in the NCI-funded research program(s) described above and the need for the Research Specialist to ensure success of the program(s). This section must explain how the Research Specialist's qualifications, experience, productivity, accomplishments, and training are critical to achieving the research goals of the Unit Director's NCI-funded research. Describe how the Research Specialist has a history of making seminal contributions to new methodologies, approaches, assays, or other research innovations that helped advance the Unit Director's research goals. Describe the Research Specialist's plans for meeting the objectives of the Unit Director's NCI-funded research program(s) over the next 5 years. This plan must also describe the Research Specialist's career goals.
Progress Report for Renewal Applications: For renewal applications, provide a Progress Report preceding the Research Program description, summarizing the previous project period's achievements, contributions, innovations, publications acknowledging the NCI grants, and other activities to support the Unit Director's NCI-funded research program(s).
Letters of Support: Institutions must include Letters of Support for the applicant who is applying for the Research Specialist Award. Applications that are missing Letters of Support will not be reviewed.
Two (2) types of Letters of Support are required for this application:
1) A letter of support from the Unit Director, which must detail the following:
a) The Unit Director must document a strong, well-established cancer research program related to the Research Specialist's area of expertise, including a high-quality research environment with key faculty members and other investigators capable of productive collaboration with the Research Specialist.
b) The Unit Director must document that they have sufficient NCI-funded research support (at least 1 full funding year remaining in the competitive segment, excluding no cost extensions or supplements, at the time of R50 award) to cover the costs of the research project(s) in excess of the allowable costs of this award.
c) Include a table attesting to the Research Specialist's level of funded effort (during relevant Federal Fiscal Year stated in Eligibility section ) on the Unit Director's NCI-funded research grants. The table must include the following: NCI grant number, award end date, and person months being paid in salary for the Research Specialist.
d) Include a statement describing the length of time that the Unit Director and the Research Specialist have been working together.
e) Specific to Renewal applications: Include a description of how the funds from the Unit Director's NCI grant(s) that were made available by the Research Specialist Award were spent to enhance the research project.
f) Provide a description of how the Research Specialist is an integral part of the institution's cancer research program and their commitment to the Research Specialist career track now and in the future.
2) At least three letters of recommendation from PDs/PIs of other research programs who can attest to the Research Specialist's qualifications and contributions to cancer research
Resource Sharing Plan:
Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed.
Not applicable for this NOFO .
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.
Not applicable for this NOFO .
All instructions in the SF424 (R&R) Application Guide must be followed.
3. Unique Entity Identifier and System for Award Management (SAM)
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIHs electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
5. Intergovernmental Review (E.O. 12372)
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
It is anticipated that the terms of award will include, but not be limited to, the following:
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.
The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organizations profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete, ineligible and/or non-compliant will not be reviewed.
Applicants are required to follow the instructions for post-submission materials, as described in the policy
1. Criteria
Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
For this particular announcement, note the following:
The Research Specialist Award applications do not require preliminary data, specific aims, and/or a detailed research plan.
Accordingly, reviewers will emphasize the following:
1) Personal accomplishments of the Research Specialist, both individually and within the context of the nominating research program/lab;
2) The Unit Director's level of accomplishments, research productivity and adequate NCI funding support;
3) The scope of the particular activity being proposed and the suitability of the Research Specialist;
4) The importance of the Research Specialist, as well as the commitment of the Unit Director, to the proper and successful functioning of the program/lab;
5) The letter of support from the Unit Director; letters of recommendation from other investigators; and AOR documentation;
6) The contributions of the Research Specialist to the nominating program/lab to date;
7) For Renewals, the committee will consider the previous project period's achievements, contributions, innovations, publications acknowledging the NCI grants, and other activities to support the Unit Director's NCI-funded research program(s).
Overall Impact
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Scored Review Criteria
Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Is the contribution of the Research Specialist important to supporting research that addresses an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? Can the Research Specialist help to achieve the goals of the Unit Director's project and improve scientific knowledge, technical capability, and/or clinical practice? How will successful completion of the goals of the program change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Specific to this NOFO:
Will the proposed research area/programs benefit in terms of productivity and contributions from the Research Specialist's participation? Is there a satisfactory and appropriate relationship of the research plan to the Research Specialist's goals and experience? How solid is the foundation of the proposed research and how strong are the proposed hypotheses?
Is the Research Specialist well suited to supporting the Unit Director's project? Does the Research Specialist have the appropriate experience and training? Has the Research Specialist demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the Research Specialist supports a collaborative project do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Specific to this NOFO :
Are the Research Specialist's level of training, experience, and competence commensurate with the purposes of the award? Does the application demonstrate the importance of the Research Specialist's role in the NCI-funded cancer research program of the Unit Director? Has the applicant been critical for and contributed to the successes of the Unit Director's cancer research program? Are the career goals of the Research Specialist appropriate for the R50? Do the letters of reference address the Research Specialist's potential for continued success/productivity?
Do the particular activities of the Research Specialist challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the Research Specialist's concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense?
Specific to this NOFO :
How innovative are the Research Specialist's contributions to the Unit Director's area of cancer research?
Are the overall strategy, methodology, and analyses appropriate to the particular activity of the applicant goals of the program(s)? Has the Research Specialist included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Has the Research Specialist presented strategies to ensure a robust and unbiased approach, as appropriate for the work being described? Are potential problems, alternative strategies, and benchmarks for success presented? If the activity is in the early stages of development, will the applicant be able to establish feasibility, and will particularly risky aspects be managed? Does the Research Specialist present adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
Specific to this NOFO :
Is it likely that the Research Specialist will develop new research directions and/or approaches that will allow progress in the Unit Director's area of cancer research? How important and reliable are the Research Specialist's contributions and data to the Unit Director's cancer research?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment, and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Specific to this NOFO :
Evaluate the level of accomplishment and commitment of the Unit Director. Does the Unit Director document that they have sufficient NCI-funded research or resource support to cover the costs of the Research Specialist's research or resource provision activities? Is there clear commitment from the Unit Director to ensure that a minimum of 6-person month effort will be devoted directly to NCI-funded research?
Additional Review Criteria
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
For Renewals, the committee will consider the progress made in the last funding period.
Revisions
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Applications from Foreign Organizations
Not Applicable.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Generally, not applicable. Reviewers should bring any concerns to the attention of the Scientific Review Officer.
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NCI, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications will receive a written critique.
Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review by the appropriate national National Cancer Advisory Board. The following will be considered in making funding decisions:
3. Anticipated Announcement and Award Dates
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement Section 2.4.4 Disposition of Applications.
1. Award Notices
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.
Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this NOFO will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:
If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.
Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS will be required to complete an HHS Assurance of Compliance form (HHS Assurance of Compliance form (HHS 690) in which the recipient agrees, as a condition of receiving the grant, to administer programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, age, sex and disability, and agreeing to comply with federal conscience laws, where applicable. This includes ensuring that entities take meaningful steps to provide meaningful access to persons with limited English proficiency; and ensuring effective communication with persons with disabilities. Where applicable, Title XI and Section 1557 prohibit discrimination on the basis of sexual orientation, and gender identity, The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html.
HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigators scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.
Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicants integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.
Not Applicable
3. Data Management and Sharing
Note: The NIH Policy for Data Management and Sharing is effective for due dates on or after January 25, 2023.
Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.
4. Reporting
When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 and 2 CFR Part 200 – Award Term and Conditions for Recipient Integrity and Performance Matters.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)
Finding Help Online: https://www.era.nih.gov/need-help (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-480-7075
Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov
Christine Siemon
National Cancer Institute (NCI)
Telephone: 240-276-6266
Email: siemonc@mail.nih.gov
Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: ncirefof@dea.nci.nih.gov
Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200.